SentinelOne, Inc. (NYSE: S) reported a narrower-than-expected loss for its fourth quarter. The company, however, but issued full-year revenue guidance below analyst estimates.
SVB Leerink analyst Mani Foroohar downgrades Decibel Therapeutics (NASDAQ:DBTX) from Outperform to Market Perform and lowers the price target from $7 to $2.